Brian Nowosielski

Anne Cassity, senior vice president of government affairs at NCPA, discusses the next moves of both PBMs and community pharmacy advocates following the signing of HR 7148.

As provisions begin rolling out over the next few years, community pharmacies will no longer be at the will of unfair reimbursement and contracting terms.

With President Trump’s signing of HR 7148, experts are now racing to get a grasp on the monumental shifts in pharmacy that will stem from this new legislation.

IBSA’s formulation of sildenafil, known as Vybrique, will hit the market in March 2026 as the first and only oral film that treats erectile dysfunction.

With infectious disease rates expected to jump as US vaccine schedules are reworked, antimicrobial stewardship programs are seeking community pharmacists.

John C. Goodman explores TrumpRx's initiatives to lower prescription drug prices, emphasizing direct-to-consumer purchasing and innovative employer strategies for savings.

Episode 7 dives into new standards of care from the American Diabetes Association and what updates are most important for pharmacists.

Through the perspectives of US health care plans and payers, researchers explore the differences in cost between single maintenance and reliever therapy and traditional therapies for treating asthma.

As lawmakers continue to deliberate on HR 7148, pharmacy law expert, Jesse Dresser, Esq, joined Drug Topics to discuss its provisions related to PBMs.

Despite a significant leap in the development of asthma therapies, depression symptoms continue to be a roadblock for improved outcomes.

If signed by President Trump in time to avoid a government shutdown, HR 7148 has potential to enforce significant change in the prescription drug supply chain.

With a multitude of concerns surrounding corticosteroids for asthma, researchers explore the overall clinical and economic burden of these drugs.

By uncovering insights on the regulatory framework regarding Rx-to-OTC rejections, researchers aim to address key challenges and concerns impeding self-care management.

This episode explores important insights on PBM reform and what pharmacies can look out for throughout 2026.

As more prescription drugs move to OTC, the pharmacist’s role in their communities are continuing to shift as well.

As pharmacists continue to take on greater clinical roles, the growing need to address mental health concerns is reaching a boiling point.

The American Academy of Pediatrics responds to recent HHS vaccine guideline changes with its own schedule for childhood and adolescent patients.

In part 2, Alyssa Billingsley, PharmD, explores some of the recent switches that made waves in the US and how they impact pharmacy operations as well as patient outcomes.

With 15 more drugs’ negotiations announced and 1 drug being renegotiated, new prices are set to take effect at the start of 2028.

Community pharmacies continue to operate in unchartered territory regarding Medicare drug price negotiations as the new IRA statute becomes an unavoidable reality for business operations.

As various regions across the country experience snowstorms, pharmacies must be proactive about ensuring minimal disruptions to their operations.

Alyssa Billingsley, PharmD, discusses the FDA’s prescription to over-the-counter drug development process and what it means for patients and pharmacies.

During the week of Roe v Wade’s 53rd anniversary, debates between pro-choice and pro-life groups are yet again reaching the national stage.

Natalie DiPietro Mager, PharmD, PhD, explores some of the policies that have bolstered maternal health care and what can still be done to further improve patient outcomes.

Natalie DiPietro Mager, PharmD, PhD, joins Drug Topics to celebrate Maternal Health Awareness Day.

Amid evolving recommendations for products like acetaminophen as well as influenza vaccines, researchers revisit the role of pharmacists in addressing adolescents’ cold and flu symptoms.

With unprecedented changes to Medicare Part D plans at the top of the year, experts from ASCP help pharmacy businesses understand key provisions under the IRA.

The new provisions would be the first major update to a Medicare Part D statute impacting the pharmacy industry in nearly 20 years.

In this episode, Natalie DiPietro Mager, PharmD, PhD, MPH, meets with Kristen Sobota, PharmD, BCPS, BCGP, and Kelly Kroustos, PharmD, CDP, to discuss caring for elderly women.

Alongside the global pharma market, OTC supplements are expected to experience over a 6% compound annual growth rate for the next 5-plus years.